Identification of Genes Involved in the Regulation of TERT in Hepatocellular Carcinoma

Overview

Journal Cancer Sci

Specialty Oncology

Date 2018 Nov 18

PMID 30447097

Citations 12

Authors

Masataka Amisaki

Hiroyuki Tsuchiya

Tomohiko Sakabe

Yoshiyuki Fujiwara

Goshi Shiota

Affiliations

Soon will be listed here.

Abstract

Telomerase reverse transcriptase (TERT) promotes immortalization by protecting telomeres in cancer cells. Mutation of the TERT promoter is one of the most common genetic alterations in hepatocellular carcinoma (HCC), indicating that TERT upregulation is a critical event in hepatocarcinogenesis. Regulators of TERT transcription are, therefore, predicted to be plausible targets for HCC treatment. We undertook a genome-wide shRNA library screen and identified C15orf55 and C7orf43 as regulators of TERT expression in HepG2 cells. Promoter assays showed that C15orf55- and C7orf43-responsive sites exist between base pairs -58 and +36 and -169 and -59 in the TERT promoter, respectively. C15orf55 upregulates TERT expression by binding to two GC motifs in the SP1 binding site of the TERT promoter. C7orf43 upregulates TERT expression through Yes-associated protein 1. The expression levels of C15orf55 and C7orf43 also correlated with that of TERT, and were significantly increased in both HCC tissues and their adjacent non-tumor tissues, compared to normal liver tissues from non-HCC patients. Analysis of 377 HCC patients in The Cancer Genome Atlas dataset showed that overall survival of patients with low levels of C15orf55 and C7orf43 expression in tumor tissues was better compared with patients with high levels of C15orf55 and/or high C7orf43 expression. These results indicate that C15orf55 and C7orf43 are involved in the incidence and progression of HCC by upregulating TERT. In conclusion, we identified C15orf55 and C7orf43 as positive regulators of TERT expression in HCC tissues. These genes are promising targets for HCC treatment.

Citing Articles

Primary tumor type prediction based on US nationwide genomic profiling data in 13,522 patients.

Huang Y, Pfeiffer S, Zhang Q Comput Struct Biotechnol J. 2023; 21:3865-3874.

PMID: 37593720 PMC: 10432138. DOI: 10.1016/j.csbj.2023.07.036.

Translocations and Gene Fusions in Sinonasal Malignancies.

Larkin R, Hermsen M, London Jr N Curr Oncol Rep. 2023; 25(4):269-278.

PMID: 36753024 PMC: 10316133. DOI: 10.1007/s11912-023-01364-x.

Identification and functional validation of HLA-C as a potential gene involved in colorectal cancer in the Korean population.

Lim E, Oh H, Kim K, Kim M, Kim Y, Kim B BMC Genomics. 2022; 23(1):261.

PMID: 35379174 PMC: 8981957. DOI: 10.1186/s12864-022-08509-5.

Telomerase Reverse Transcriptase Promoter Mutations in Human Hepatobiliary, Pancreatic and Gastrointestinal Cancer Cell Lines.

Hirata M, Fujita K, Fujihara S, Mizuo T, Nakabayashi R, Kono T In Vivo. 2022; 36(1):94-102.

PMID: 34972704 PMC: 8765179. DOI: 10.21873/invivo.12680.

Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics.

Macias R, Monte M, Serrano M, Gonzalez-Santiago J, Martin-Arribas I, Simao A Aging (Albany NY). 2021; 13(19):23416-23434.

PMID: 34633987 PMC: 8544321. DOI: 10.18632/aging.203620.

References

Llovet J, Hernandez-Gea V . Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res. 2014; 20(8):2072-9. DOI: 10.1158/1078-0432.CCR-13-0547. View

Kyo S, Takakura M, Taira T, Kanaya T, Itoh H, Yutsudo M . Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res. 2000; 28(3):669-77. PMC: 102554. DOI: 10.1093/nar/28.3.669. View

Tahara H, Nakanishi T, Kitamoto M, Nakashio R, Shay J, Tahara E . Telomerase activity in human liver tissues: comparison between chronic liver disease and hepatocellular carcinomas. Cancer Res. 1995; 55(13):2734-6. View

Shay J, Wright W . The reactivation of telomerase activity in cancer progression. Trends Genet. 1996; 12(4):129-31. DOI: 10.1016/0168-9525(96)30018-8. View

Oh B, Kim H, Park Y, Yoo J, Choi J, Kim K . High telomerase activity and long telomeres in advanced hepatocellular carcinomas with poor prognosis. Lab Invest. 2007; 88(2):144-52. DOI: 10.1038/labinvest.3700710. View

Takase S, Kurokawa R, Arai D, Kanemoto Kanto K, Okino T, Nakao Y . A quantitative shRNA screen identifies ATP1A1 as a gene that regulates cytotoxicity by aurilide B. Sci Rep. 2017; 7(1):2002. PMC: 5435677. DOI: 10.1038/s41598-017-02016-4. View

Zucman-Rossi J, Villanueva A, Nault J, Llovet J . Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology. 2015; 149(5):1226-1239.e4. DOI: 10.1053/j.gastro.2015.05.061. View

Zhao B, Wei X, Li W, Udan R, Yang Q, Kim J . Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007; 21(21):2747-61. PMC: 2045129. DOI: 10.1101/gad.1602907. View

Deng Y, Chan S, Chang S . Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev Cancer. 2008; 8(6):450-8. PMC: 3688269. DOI: 10.1038/nrc2393. View

10.

Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300. DOI: 10.3322/caac.20073. View

11.

Griffith J, Comeau L, Rosenfield S, Stansel R, Bianchi A, Moss H . Mammalian telomeres end in a large duplex loop. Cell. 1999; 97(4):503-14. DOI: 10.1016/s0092-8674(00)80760-6. View

12.

Lin S, Nascimento E, Gajera C, Chen L, Neuhofer P, Garbuzov A . Distributed hepatocytes expressing telomerase repopulate the liver in homeostasis and injury. Nature. 2018; 556(7700):244-248. PMC: 5895494. DOI: 10.1038/s41586-018-0004-7. View

13.

Zender L, Spector M, Xue W, Flemming P, Cordon-Cardo C, Silke J . Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 2006; 125(7):1253-67. PMC: 3026384. DOI: 10.1016/j.cell.2006.05.030. View

14.

French C . Pathogenesis of NUT midline carcinoma. Annu Rev Pathol. 2011; 7:247-65. DOI: 10.1146/annurev-pathol-011811-132438. View

15.

Nakayama J, Tahara H, Saito M, Ito K, Nakamura H, Nakanishi T . Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet. 1998; 18(1):65-8. DOI: 10.1038/ng0198-65. View

16.

Reynoird N, Schwartz B, Delvecchio M, Sadoul K, Meyers D, Mukherjee C . Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains. EMBO J. 2010; 29(17):2943-52. PMC: 2944051. DOI: 10.1038/emboj.2010.176. View

17.

Kim N, Piatyszek M, Prowse K, Harley C, WEST M, Ho P . Specific association of human telomerase activity with immortal cells and cancer. Science. 1994; 266(5193):2011-5. DOI: 10.1126/science.7605428. View

18.

Chiba K, Lorbeer F, Shain A, McSwiggen D, Schruf E, Oh A . Mutations in the promoter of the telomerase gene contribute to tumorigenesis by a two-step mechanism. Science. 2017; 357(6358):1416-1420. PMC: 5942222. DOI: 10.1126/science.aao0535. View

19.

Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C . The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell. 2011; 147(4):759-72. DOI: 10.1016/j.cell.2011.09.048. View

20.

Wu X, Huang C, He X, Tian Y, Zhou D, He Y . Feedback regulation of telomerase reverse transcriptase: new insight into the evolving field of telomerase in cancer. Cell Signal. 2013; 25(12):2462-8. DOI: 10.1016/j.cellsig.2013.08.009. View